Q2 2015 13F Holders as of 30 Jun 2015
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
88
-
Total 13F shares, excl. options
-
20,482,234
-
Shares change
-
-51,094
-
Total reported value, excl. options
-
$655,028,876
-
Value change
-
+$16,033,415
-
Number of buys
-
66
-
Number of sells
-
-26
-
Price
-
$31.98
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q2 2015
100 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2015.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 88 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 20,482,234 shares
of 104,661,494 outstanding shares and own 20% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4,592,047 shares), NQ HCIF GP, Ltd. (3,096,650 shares), FRANKLIN RESOURCES INC (3,066,887 shares), Bank of New York Mellon Corp (1,840,141 shares), JPMORGAN CHASE & CO (1,396,505 shares), Polar Capital LLP (1,130,409 shares), BlackRock Fund Advisors (720,999 shares), Arrowpoint Asset Management, LLC (552,972 shares), VANGUARD GROUP INC (448,457 shares), and WADDELL & REED FINANCIAL INC (310,350 shares).
This table shows the top 88 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.